The Canadian COVID-19 Prospective Cohort Study

Covid19 Clinical Trial

— CANCOV  

Official title:

The Canadian COVID-19 Prospective Cohort Study

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT05125510
• Other study ID #: 20-5403
• Secondary ID: CTO 2157
• Status: Active, not recruiting
• Start date: June 17, 2020
• Est. completion date: December 2027

Study information

• Verified date: June 2023
• Source: University Health Network, Toronto
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The CANCOV study will be the first Canadian study to provide a comprehensive evaluation of early, and 1-year, outcomes of outpatient and hospitalized COVID-19 survivors and their family caregivers, their varied trajectories and associated clinical risk factors. The overall objectives are to determine short- (in hospital) and longer-term (1, 3, 6 and 12 months post-acute hospital discharge) outcomes COVID-19+ patients across the spectrum of symptom severity, including outpatients and inpatients from GIM and ICU wards and their caregivers, and the clinical, sociodemographic, multi-omic predictors of these outcomes. By leveraging expertise from investigators across disciplines and divisions, this study presents a suite of complementary projects that explore the genetic, transcriptomic, epigenomic and immunologic evaluation of COVID-19 infection across the illness and recovery trajectory during the acute illness and in the context of multidimensional long-term outcomes. As there continues to be need for longer term follow up and research on Long-COVID, this study has added an optional extension to include 2-year, 3-year, 4-year and 5 year outcomes.

Description:

In December 2019, a novel coronavirus (COVID-19)-infected pneumonia was identified in Wuhan, China, and is a current global pandemic. Early studies are emerging, but it is still unclear what may determine better or worse outcomes for these patients and their caregivers, and the detailed nature of long-term consequences from this infection. Current data suggest that 80-85% of patients infected with COVID-19 have mild symptoms and are not hospitalized. Of those who are hospitalized, 60-80% will be discharged from hospital after a few days, and 20-40% may require treatment in an intensive care unit (ICU) and/or mechanical ventilation (approximately 4-6% of all COVID-19 positive patients). The determining factors of these varied clinical paths are urgently needed and unknown. The CANCOV investigator group is conducting a national Canadian COVID-19 Prospective Cohort Study (CANCOV). This will be a multi-centre, one-year follow-up of 1000 COVID-19 patients who are hospitalized in acute care hospitals (those admitted to general internal medicine (GIM) wards, and/or ICUs) and their caregivers, and 1000 non-hospitalized patients (those who were tested positive and asked to isolate at home) in participating centres across Canada. In addition, a cohort of 500-1000 patients who do not have a COVID-19 positive test but who present with a clinical diagnosis of COVID-19 will be included for investigation and comparison. The overall objectives are to determine short- (in hospital, and 2-week outcome for non-hospitalized patients) and longer-term (1, 3, 6 and 12 months post-acute hospital discharge or post diagnosis for outpatients) outcomes in patients and their caregivers, and the clinical, sociodemographic, genetic/ transcriptomic/epigenomic/immunological predictors of these outcomes. Due to patients with 'long-COVID' syndrome, the investigators have added an optional study extension for an additional 48 months, up to 5 years follow up. By leveraging expertise from investigators across disciplines and divisions, this study presents a suite of complementary projects that explore the genetic, transcriptomic, epigenomic and immunological evaluation of COVID-19 infection across the illness and recovery trajectory in mild as well as acute illness and in the context of multidimensional long-term outcomes. The investigators will access electronic data through the GEMINI network, and explore Artificial Intelligence (AI) analyses and linkages through Institute of Clinical and Evaluative Sciences (ICES) data. This project will contribute new knowledge to outcomes in patients with COVID-19 infections and will inform large-scale public health planning, clinical care, and ongoing resource needs.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 2176
• Est. completion date: December 2027
• Est. primary completion date: December 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 16 Years and older

Eligibility

Inclusion Criteria:

Patients

1. > 16 years of age

2. COVID-19+ test Antibody Negative/Presumed COVID-19 comparator cohort

1. > 16 years of age

2. NO COVID-19+ test (either by nasal swab or antibody)

3. Experienced symptoms

4. Strong epidemiologic links suggesting probable COVID-19 infection (such as household or occupational contacts and close timing of their symptoms to an index case.

Caregiver:

1. Family caregivers of hospitalized COVID-19+ patients who are participating in the study. Family caregivers are defined as the family member or friend who is responsible for providing and/or coordinating all the COVID-19 survivors' post-hospital care without financial compensation. They will be included if they are able to read and speak English and are over the age of 18 years.

Exclusion Criteria:

1. Anticipated death or withdrawal of life sustaining treatment within 48 hours.

2. Catastrophic neurological injury in the opinion of the attending physician (e.g. Grade V SAH or massive CVA).

3. Patient unlikely to comply with follow-up.

4. Physician refusal (only for hospitalized patients).

5. Patient or SDM (substitute decision maker) refuses consent.

6. No next of kin or SDM available (if patient unable to provide consent).

Related Conditions & MeSH terms

• COVID-19
• Covid19

Locations

Country	Name	City	State
Canada	Alberta Health Services	Calgary	Alberta
Canada	William Osler Health System	Etobicoke	Ontario
Canada	St Joseph's Health Centre	Hamilton	Ontario
Canada	McGill University Health Centre	Montreal	Quebec
Canada	Montreal Jewish General	Montréal	Quebec
Canada	The Ottawa Hospital	Ottawa	Ontario
Canada	University of Sherbrooke	Sherbrooke	Quebec
Canada	Hospital for Sick Children	Toronto	Ontario
Canada	Michael Garron Hospital (Toronto East General Hospital)	Toronto	Ontario
Canada	Mount Sinai Hospital	Toronto	Ontario
Canada	Unity Health (St Michaels Health Centre_	Toronto	Ontario
Canada	University Health Network, Osteoporosis Department	Toronto	Ontario
Canada	Providence Healthcare	Vancouver	British Columbia
Canada	Health Sciences Centre and St. Boniface Hospital and Grace Hospital	Winnipeg	Manitoba

Sponsors (6)

Lead Sponsor	Collaborator
University Health Network, Toronto	Canadian Frailty Network, Canadian Institutes of Health Research (CIHR), The Hospital for Sick Children, Unity Health, University of Toronto

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Functional Independence Measure (FIM) or acute FIM	FIM is a measure of self-care, sphincter control, mobility, locomotion, communication, social and cognitive skills that has been validated and standardized in spinal cord and stroke populations. The acuteFIM is a subscale of the FIM and adapted to patients in hospital.	1 year post diagnosis/admission
Secondary	Functional Independence Measure (FIM) or acute FIM	FIM is a measure of self-care, sphincter control, mobility, locomotion, communication, social and cognitive skills that has been validated and standardized in spinal cord and stroke populations. The acuteFIM is a subscale of the FIM and adapted to patients in hospital.	1,3 and 6 months post diagnosis/admission
Secondary	Six Minute Walking Test (6MWT) with oximetry	Subjects walk as far as they can in six minutes while receiving maximum encouragement. It is simple to execute, inexpensive, standardized and gives a tangible measure of functional exercise capacity. It has been validated in survivors of critical illness. The 6MWT will be conducted according to American Thoracic Society standards.	admission/diagnosis to 1,3,6 and 12 months. Extension 18, 24, 30, 36, 42, 48, 54, 60 months.
Secondary	Pulmonary Function Testing (spirometry)	Non-invasive measures of lung volume, capacity, rates of flow, and gas exchange through a mouthpiece connected to a spirometer and are used for screening and diagnosis of lung disorders. These tests will be conducted according to American Thoracic Society standards. For non-hospitalized and hospitalized non-ICU participants, spirometry will be conducted only if clinically indicated.	admission/diagnosis to 1,3,6 and 12 months. Extension 18, 24, 30, 36, 42, 48, 54, 60 months.
Secondary	Medical Research Council (MRC) Score for Muscle Strength	This score measures level of muscle strength in proximal and distal muscle groups on a scale from 0-5 where 0 indicates no muscle flexion, and 5 indicates full muscle function against gravity and against resistance. Muscle strength in the upper extremities (arm, forearm, wrist) and lower extremities (leg, knee, foot) will be tested.	admission/diagnosis to 1,3,6 and 12 months. Extension 18, 24, 30, 36, 42, 48, 54, 60 months.
Secondary	Medical Outcomes Study Short Form -36 Questionnaire (SF-36)	The self-administered SF-36 evaluates eight health concepts: physical functioning, role functioning-physical, bodily pain, general health, vitality, social functioning, role functioning-emotional, and mental health. Previous studies have used this instrument in survivors of critical illness and it takes approximately 15 minutes to complete. Used for all patient + caregiver cohorts.	admission/diagnosis to 1,3,6 and 12 months. Extension 18, 24, 30, 36, 42, 48, 54, 60 months.
Secondary	Patient Health Questionnaire (PHQ-9)	The PHQ-9 is a validated, multipurpose instrument for screening, diagnosing, monitoring and measuring the severity of depression. It incorporates DSM-IV depression diagnostic criteria with other leading major depressive symptoms into a brief self-report tool. The PHQ-9 is brief and useful in clinical practice. The PHQ-9 is completed by the patient in minutes and is rapidly scored by the clinician. The PHQ-9 can also be administered repeatedly, which can reflect improvement or worsening of depression in response to treatment. Used for all patient + caregiver cohorts.	admission/diagnosis to 1,3,6 and 12 months. Extension 18, 24, 30, 36, 42, 48, 54, 60 months.
Secondary	General Anxiety Assessment Form (GAD-7)	The GAD-7 is a valid and efficient tool for screening for generalized anxiety disorder and assessing its severity in clinical practice and research. It is easy-to-use, self-administered patient questionnaire that can be completed in minutes. Used for all patient + caregiver cohorts.	admission/diagnosis to 1,3,6 and 12 months. Extension 18, 24, 30, 36, 42, 48, 54, 60 months.
Secondary	PCL-5 Trauma Score	The PCL-5 is a validated, reliable, 20-item self-report measure that assesses the 20 DSM-5 symptoms of Post-Traumatic Stress Disorder (PTSD). It takes approximately 5-10 minutes to complete. Used for all patient + caregiver cohorts.	admission/diagnosis to 1,3,6 and 12 months. Extension 18, 24, 30, 36, 42, 48, 54, 60 months.
Secondary	Connor-Davidson Resiliency Scale (CD-RISC)	ICU PATIENT + iCU CAREGIVER COHORT: The CD-RISC-10 is a validated, reliable 10-item measure that assesses resilience or how well one is equipped to bounce back after stressful events, tragedy, or trauma. The CD-RISC-10 scale is comprised of ten of the original 25 items from the CD-RISC25 scale. Total scores range from 0-40.; The CD-RISC-2 is a shorter version with 2 questions and captures the essence of the whole instrument and will be used in the non-hospitalized cohort, the hospitalized non-ICU cohort, and non-ICU caregiver cohort.	admission/diagnosis to 1,3,6 and 12 months. Extension 18, 24, 30, 36, 42, 48, 54, 60 months.
Secondary	Reintegration to Normal Living Index (RNLI)	This short self-administered assessment tool will determine the degree to which participants reintegrate into normal social activities such as recreation, mobility in the community and interaction in family or other relationships. This tool has been validated in community living adults with mobility limitations.	admission/diagnosis to 1,3,6 and 12 months. Extension 18, 24, 30, 36, 42, 48, 54, 60 months.
Secondary	BORG Dypsnea scale	This short assessment tool assesses perceived exertion using a 10 point scale as assessed by the patient's experience.	admission/diagnosis to 1,3,6 and 12 months. Extension 18, 24, 30, 36, 42, 48, 54, 60 months.
Secondary	Clinical Frailty Scale Score (CFS)	The CFS is a reliable and validated scale shown to be a strong predictor of institutionalization and mortality in older and also critically ill patients across differing age groups.	admission/diagnosis to 1,3,6 and 12 months. Extension 18, 24, 30, 36, 42, 48, 54, 60 months.
Secondary	Rapid Geriatric Assessment	The Rapid Geriatric Assessment (RGA) is a tool developed to quickly identify four geriatric syndromes including frailty, sarcopenia, anorexia of aging and cognitive dysfunction and takes less than 4 minutes to administer. The components of the RGA are the FRAIL for frailty, SARC-F for sarcopenia, SNAQ for anorexia of aging and the Rapid Cognitive Screen which is derived from the St. Louis University Mental Status Examination. All the screening tools have been validated in multiple continents and are available in up to 30 languages.	admission/diagnosis to 1,3,6 and 12 months. Extension 18, 24, 30, 36, 42, 48, 54, 60 months.
Secondary	Stigma Scale (SS)	There is no COVID-19 specific validated stigma scale. The Investigators have modified a short stigma scale that has been validated to assess enacted and internalized stigma and psychological distress in patients with tuberculosis. The investigators will be testing this modified scale out in a subgroup of patients prior to using it in our wider cohorts.	admission/diagnosis to 1,3,6 and 12 months. Extension 18, 24, 30, 36, 42, 48, 54, 60 months.
Secondary	Mortality	The determinants of hospital mortality and 1-year outcome will inform risk stratification and outcome.	admission/diagnosis to 1 year. Extension 18, 24, 30, 36, 42, 48, 54, 60 months.
Secondary	Pattern and Cost of Post-hospital discharge Healthcare Utilization (Resources and Costs)	Health services use after enrollment including hospitalization, emergency department visits, outpatient contact with physicians including virtual visits and phone calls.	admission/diagnosis to 1,3,6, and 12 months. Extension 18, 24, 30, 36, 42, 48, 54, 60 months.
Secondary	Medical Outcomes Study Social Support Scale (SS)	Assessment of social support using this scale will be used for the family caregiver cohort only.	baseline to 1,3,6 and 12 months. Extension 18, 24, 30, 36, 42, 48, 54, 60 months.
Secondary	Care-giving Impact Scale (CIS)	participation in valued activities will be assessed using this scale for the family caregiver cohort only.	baseline to 1,3,6 and 12 months. Extension 18, 24, 30, 36, 42, 48, 54, 60 months.
Secondary	Care-giving Assistance Scale (CAS)	level of care provided to the ICU survivor in terms of activities of daily living, instrumental activities and medical care will be evaluated in the family caregiver cohort only.	baseline to 1,3,6 and 12 months. Extension 18, 24, 30, 36, 42, 48, 54, 60 months.
Secondary	Pearlin's Mastery Scale	This scale will be used to assess caregivers' sense of control over life.	baseline to 1,3,6 and 12 months. Extension 18, 24, 30, 36, 42, 48, 54, 60 months.
Secondary	Personal Gain Scale	This scale will be used to assess caregivers' personal development as a result of providing care.	baseline to 1,3,6 and 12 months. Extension 18, 24, 30, 36, 42, 48, 54, 60 months.